Evaluation of Representation of Women As Authors in Pivotal Trials Supporting US Food and Drug Administration Approval of Novel Hematological Drugs

被引：0
|
作者：
Farooq, Muhammad Zain [1 ]
Sohail, Aruba [2 ]
Fatima, Areej [2 ]
Jawed, Areesha [2 ]
Jaglal, Michael [3 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Hematol Oncol, Tampa, FL USA
[2] Dow Univ Hlth Sci, Karachi, Pakistan
[3] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-168238
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：10775 / 10776
页数：2
相关论文
共 50 条
  • [1] Evaluation of Representation of Women as Authors in Pivotal Trials Supporting US Food and Drug Administration Approval of Novel Cardiovascular Drugs
    Shahid, Izza
    Khan, Muhammad Shahzeb
    Sohail, Aruba
    Khan, Safi U.
    Greene, Stephen J.
    Fudim, Marat
    Michos, Erin D.
    [J]. JAMA NETWORK OPEN, 2022, 5 (02)
  • [2] Ten-Year Trends in Enrollment of Women and Minorities in Pivotal Trials Supporting Recent US Food and Drug Administration Approval of Novel Cardiometabolic Drugs
    Khan, Muhammad Shahzeb
    Shahid, Izza
    Siddiqi, Tariq Jamal
    Khan, Safi U.
    Warraich, Haider J.
    Greene, Stephen J.
    Butler, Javed
    Michos, Erin D.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (11):
  • [3] Evaluation of the fragility of pivotal trials used to support US Food and Drug Administration approval for plaque psoriasis
    Shalhout, Sophia Z.
    Bloom, Romi
    Drake, Lynn
    Miller, David M.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 84 (02) : 354 - 360
  • [4] Participation of African American Persons in Clinical Trials Supporting US Food and Drug Administration Approval of Cancer Drugs
    Al Hadidi, Samer
    Mims, Martha
    Miller-Chism, Courtney Nicole
    Kamble, Rammurti
    [J]. ANNALS OF INTERNAL MEDICINE, 2020, 173 (04) : 320 - +
  • [5] Magnitude of clinical benefit of randomized controlled trials supporting US Food and Drug Administration approval of drugs for solid tumours
    Molto Valiente, C.
    Amir, E.
    Fernandez, A. Ocana
    Templeton, A.
    del Carpio Huerta, L.
    Del Paggio, J.
    Barnadas, A.
    Booth, C.
    Tibau, A.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [6] Changes in primary outcome and sample size measures after initiation of accrual among trials supporting approval of drugs for hematological malignancies by the US food and drug administration
    Amitai, Irina
    Raanani, Pia
    Shepshelovich, Daniel
    [J]. LEUKEMIA & LYMPHOMA, 2020, 61 (09) : 2216 - 2220
  • [7] Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms
    Al Hadidi, Samer
    Schinke, Carolina
    Thanendrarajan, Sharmilan
    Zangari, Maurizio
    van Rhee, Frits
    [J]. JAMA NETWORK OPEN, 2022, 5 (04) : E228161
  • [8] Participation of the elderly, women, and minorities in pivotal trials supporting 2011-2013 US Food and Drug Administration approvals
    Downing, Nicholas S.
    Shah, Nilay D.
    Neiman, Joseph H.
    Aminawung, Jenerius A.
    Krumholz, Harlan M.
    Ross, Joseph S.
    [J]. TRIALS, 2016, 17
  • [9] Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017
    Zhang, Audrey D.
    Puthumana, Jeremy
    Downing, Nicholas S.
    Shah, Nilay D.
    Krumholz, Harlan M.
    Ross, Joseph S.
    [J]. JAMA NETWORK OPEN, 2020, 3 (04)
  • [10] Magnitude of clinical benefit of trials supporting US Food and Drug Administration (FDA) approval of breakthrough and non-breakthrough drugs
    Molto Valiente, C.
    Borrell, M.
    Hwang, T.
    Gich Saladich, I.
    Barnadas, A.
    Amir, E.
    Kesselheim, A.
    Tibau, A.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
12345